地氯雷他定联合通窍鼻炎胶囊治疗过敏性鼻炎

Desloratadine combined with Tongqiao Biyan capsule for the treatment of allergic rhinitis

目的探讨地氯雷他定联合通窍鼻炎胶囊治疗过敏性鼻炎的临床效果。方法选取2018年2月至2020年2月在宁波大学医学院附属医院诊治的过敏性鼻炎患者100例, 采用随机数字表法分为对照组和观察组, 每组50例。对照组给予地氯雷他定分散片治疗, 观察组给予地氯雷他定+通窍鼻炎胶囊治疗, 治疗21 d。观察患者临床症状改善、炎性因子水平变化等情况。结果观察组治疗后鼻痒、鼻塞、流涕、喷嚏症状评分分别为(1.42±0.10)分、(1.20±0.13)分、(1.25±0.13)分、(1.33±0.14)分, 均显著低于对照组的(1.80±0.12)分、(1.68±0.15)分、(1.68±0.11)分、(1.68±0.13)分(t=17.20、17.10、17.85、12.95, 均P < 0.001)。观察组治疗后白细胞介素4、6、8水平分别为(16.12±5.05)ng/L、(5.33±2.10)ng/L、(37.16±9.80)ng/L, 均显著低于对照组的(21.52±5.58)ng/L、(8.12±2.15)ng/L、(48.55±9.65)ng/L, 干扰素γ水平为(26.58±2.58)ng/L, 显著高于对照组的(23.68±2.69)ng/L, 均差异有统计学意义(t=5.07、6.56、5.86、5.50, 均P < 0.001)。观察组治疗后生活质量调查问卷总评分为(61.58±8.57)分, 显著高于对照组的(40.98±8.35)分(t=12.17, P < 0.001)。观察组不良反应总发生率为10.00%(5/50), 对照组为14.00%(7/50), 两组差异无统计学意义(χ^(2)=0.38, P > 0.05)。结论地氯雷他定联合通窍鼻炎胶囊治疗过敏性鼻炎患者, 可明显改善症状, 提高控制炎症的效果, 且不增加药物不良反应。

Objective To investigate the effects of desloratadine combined with Tongqiao Biyan capsule on allergic rhinitis.Methods 100 patients with allergic rhinitis who received treatment in The Affiliated Hospital of Medical College of Ningbo University from February 2018 to February 2020 were included in this study.They were randomly assigned to receive treatment with either desloratadine tablets(control group,n=50)or desloratadine tablets combined with Tongqiao Biyan capsule(observation group,n=50)for 21 days.Improvement in clinical symptoms and changes in inflammatory factors were observed in each group.Results Scores of nasal itch,nasal obstruction,runny nose,and sneezing in the observation group were(1.42±0.10)points,(1.20±0.13)points,(1.25±0.13)points,and(1.33±0.14)points,respectively,which were significantly lower than those in the control group[(1.80±0.12)points,(1.68±0.15)points,(1.68±0.11)points,(1.68±0.13)points,t=17.20,17.10,17.85,12.95,all P<0.001].After treatment,interleukin-4,-6,-8 levels in the observation group were(16.12±5.05)ng/L,(5.33±2.10)ng/L,(37.16±9.80)ng/L,respectively,which were significantly lower than those in the control group[(21.52±5.58)ng/L,(8.12±2.15)ng/L,(48.55±9.65)ng/L,t=5.07,6.56,5.86,all P<0.05].Interferon-γlevel was significantly higher in the observation group than in the control group[(26.58±2.58)ng/L vs.(23.68±2.69)ng/L,t=5.50,P<0.001].After treatment,the total score of the quality of life questionnaire was significantly higher in the observation group than in the control group[(61.58±8.57)points vs.(40.98±8.35)points,t=12.17,P<0.001].There was no significant difference in total incidence of adverse reactions between observation and control groups[10.00%(5/50)vs.14.00%(7/50),χ^(2)=0.38,P>0.05].Conclusion Desloratadine combined with Tongqiao Biyan capsule can better improve the symptoms of allergic rhinitis and better reduce inflammation without increasing adverse drug reactions compared with desloratadine alone.